Our Mission
We are developing innovative drugs to target challenging protein-protein interactions in cancer, leveraging our proprietary phenotypic drug discovery platform. Having successfully completed hit validation for our first program, we are now seeking seed investors to advance to the lead identification stage.
Our Science
We are pioneering a first-in-class strategy to selectively disable oncogenic STAT5 signaling at its source. In hematologic malignancies such as acute myeloid leukemia (AML), pathological STAT5 activity is driven by oligomerization โ a mechanism distinct from its essential physiological dimerization in healthy cells. By specifically targeting STAT5 oligomerization with small molecules, we aim to shut down malignant signaling while preserving normal cellular function.
This precision-based approach has the potential to redefine how STAT5-driven cancers are treated โ delivering highly effective therapies with reduced side effects and expanding the boundaries of what is considered druggable.
Read more about our science.
Our Team
RIANA Therapeutics is a female-led biotechnology company with a small focused core team combining expertise in molecular oncology, STAT5 biology, and small-molecule drug discovery. RIANA is led by co-founder and CEO Anna Orlova, and co-founder and CBO Christine Ruckenbauer.
RIANA is supported by a distinguished Scientific Advisory Board with deep expertise in STAT5 biology, medicinal chemistry, and oncology drug development, as well as strategic and financial guidance.
Klick here to learn more about our team.
RIANA NEWS
Austrian Start-up Award PHรNIX 2026 Finalist
RIANA Therapeutics has been nominated as a finalist in the Spin-off category of the Austrian Grรผndungspreis PHรNIX 2026! Initiatives like PHรNIX help make visible how research can translate into real-world impact, something essential for the development of the biotech ecosystem in Austria. The winners will be announced in Vienna on 12 March. Link to Phรถnixโฆ
Keep reading
Happy 3rd Birthday, RIANA!
Time is rushing – especially in a buzzing and vibrant field like biotech. Three years ago, RIANA Therapeutics started with a bold scientific vision and the belief that small, focused teams can tackle big challenges. Today, we are proud of how far weโve come โ from early scientific validation to advancing our STAT5 program withโฆ
Keep readingMeet us at these upcoming conferences 2026
04.-05. March Sachs European Life Science CEO Forum, Zurich 23.-25. March BioSpring & RESI, Lisboa 27.-28. April BioVaria, Munich 03.-05. May Swiss Biotech Days, Basel 04.-06. May BioEquityEurope, Prague We look forward to networking with venture capital, business angels and industry leaders, discussing how RIANAโs STAT5 inhibitor program is paving the way for new treatmentsโฆ
Keep reading
RIANA Therapeutics 